Abstract: 20,23-disubstituted mycaminosyltylonolide derivatives and use of the same in the field of the prophylaxis and treatment of pasteurellosis are disclosed. The di-substituents are peperidino optionally substituted with one or two methyl groups. The derivatives have selective antibacterial activity against Pasteurella.

Abstract: The present invention relates to an oxetane derivative represented by the general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are each an acyl group and R.sub.3 is a hydrogen atom or a lower alkyl group, which is useful as an intermediate for the preparation of a compound having a (bishydroxymethyl)oxetane structure in its saccharide moiety, for example, oxetanosine, and a process for the preparation of the same.

Abstract: This invention relates to a novel 4'-demethyl-4-epipodophylltoxin derivative of the formula: ##STR1## (wherein R.sub.1 is a lower alkyl group; X.sub.1 and X.sub.2 are each a hydroxyl group or an amino group substituted by one or two lower alkyls, provided that either one of X.sub.1 and X.sub.2 is an amino group substituted by one or two lower alkyls and the other is a hydroxyl group) and salts thereof.

Abstract: This invention relates to novel 4'-demethyl-4-epipodophyllotoxin derivatives represented by the general formula (I), and salts thereof: ##STR1## wherein R is a lower alkyl group, and X.sub.1 and X.sub.2 are independently a hydroxyl group or an amino group, the one being an amino group and the other being a hydroxyl group. These novel derivatives have a high carcinostatic activity and a relatively high water solubility and hence are expected to be useful as carcinostatics.

Abstract: This invention relates to 2'-deoxy-oxanosine represented by the following formula: ##STR1## and process for the preparation thereof. This new compound exhibits a growth inhibiting action to gram-negative bacteria and has a carcinostatic action.

Abstract: The novel antibiotic, oxanosine, having the structure ##STR1## inhibits the growth of Gram-negative bacteria and has antiviral activity. It is produced by cultivation of an oxanosine-producing microorganism of the genus Streptomyces, preferably Streptomyces capreolus MG265-CF3, ATCC No. 31963.

Abstract: The novel antibiotic, oxanosine, having the structure ##STR1## inhibits the growth of Gram-negative bacteria and has antiviral and carcinostatic activity. It is produced by cultivation of an oxanosine-producing microorganism of the genus Streptomyces, preferably Streptomyces capreolus MG265-CF3, ATCC No. 31963.

Abstract: Novel antibiotics cleomycins represented by the formula ##STR1## wherein R is a terminal amino residue of the cleomycin. These compounds are useful as a chemotherapeutic agent for treating cancer and bacterial infections.

Abstract: N-methylbleomycins represented by the general formula ##STR1## which are useful as antitumor agents and bactericides; a method of preparing the same; and intermediate products in the preparation thereof.

Abstract: Bestatin, which is [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine, and related compounds which inhibit aminopeptidase B, leucino aminopeptidase and Bleomycin hydrolase, enhance the anti-tumor effect of Bleomycin and exhibit an antifertility effect were synthesized and tested.

Abstract: Novel 3-[(S)-1'-phenylethylamino]propylaminobleomycin obtained by reacting a reactive derivative of the carboxyl group of bleomycinic acid with N-[(S)-1'-phenylethyl]-1,3-diaminopropane, a non-toxic salt of said novel bleomycin, and a method for producing the novel bleomycin. Because of much reduction in the side effect causing pulmonary fibrosis, the novel bleomycin is more useful than a commercial bleomycin complex which gives rise to said undesirable side effect.

Abstract: Novel 3-[(S)-1'-phenylethylamino]propylaminobleomycin obtained by reacting a reactive derivative of the carboxyl group of bleomycinic acid with N-[(S)-1'-phenylethyl]-1,3-diaminopropane, a non-toxic salt of said novel bleomycin, and a method for producing the novel bleomycin. Because of much reduction in the side effect causing pulmonary fibrosis, the novel bleomycin is more useful than a commercial bleomycin complex which gives rise to said undesirable side effect.

Abstract: Bestatin, which is [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine, and related compounds which inhibit aminopeptidase B, leucino aminopeptidase and Bleomycin hydrolase, enhance the anti-tumor effect of Bleomycin and exhibit an antifertility effect were synthesized and tested.

Abstract: By adding a specific amine in culturing under aerobic conditions actinomycetales capable of producing phleomycin group antibiotics, which have been inoculated into a nutrient medium to produce antitumor phleomycin group antibiotics, it is possible to obtain specific phleomycin group antibiotics having a side chain structure corresponding to said amine. The phleomycin group antibiotics thus produced are collected from the culture medium in a conventional way.

Abstract: By thermal decomposition of 3-(S,S-dimethylmercapto)propylaminobleomycin, there is easily obtained 3-(methylmercapto)propylaminobleomycin which is a useful antibiotic substance having an extremely high antimicrobial activity and a carcinostartic activity with low toxicity.

Abstract: This invention is concerned with the oxidative conversion of an unstable phleomycin group to a stable bleomycin group antibiotic having the partial structure: ##SPC1##By treatment with potassium ferricyanide or manganese dioxide.

Abstract: A novel process for producing antibiotics bleomycins by innoculating and aerobically culturing in a nutrient source-containing medium a bleomycin-producing strain belonging to the actinomyces, wherein the culture is effected in the presence of an amino compound having at least one ##STR1## group and at least one basic group selected from amino, imino, guanidino, amidino and sulfonium groups and nitrogen-containing cyclic compounds, or in the presence of a compound convertible in the culture liquor to such amino compound as mentioned above, thereby selectively producing a known or novel bleomycin component corresponding to the said amino compound or to an amino compound derived from the above-mentioned compound, and then the known or novel bleomycin is recovered by known means from the culture medium.